Abiomed Inc.

Abiomed Inc., a for-profit medical device manufacturer headquartered in Danvers, Massachusetts, sells Impella percutaneous cardiac support devices, catheters, controllers, and associated maintenance and repair services to the federal government as a prime contractor on sole-source purchase orders and delivery orders, with no identified subcontractors and no SBA set-aside designations across its footprint.

Abiomed operates exclusively as a prime contractor across 1,589 awards over the past several years, competing full-and-open with no small business set-asides. The company manufactures specialized temporary mechanical circulatory support systems—primarily the Impella platform—for patients experiencing heart failure or cardiogenic shock during high-risk cardiovascular interventions. Recent representative work includes a $127,904 maintenance services purchase order from Veterans Integrated Service Network 19 (awarded September 30, 2026) covering preventive and corrective maintenance, OEM-certified replacement parts, depot-level repairs, loaner equipment, and technical support for Automated Impella Controller consoles at Rocky Mountain Regional VA Medical Center through August 31, 2031; a $130,000 purchase order from VISN 16 (awarded July 1, 2026) for preventative maintenance of two Abiomed Impella 598 devices at the John L. McClellan Memorial Veterans Hospital in Little Rock, Arkansas through June 30, 2031; and a $291,000 purchase order from VISN 12 (awarded May 1, 2025) for maintenance of six Abiomed cardiac support machines across three Milwaukee-area VA Medical Centers through April 30, 2030. All recent awards are justified as sole-source procurements under FAR 6.302-1 or FAR 12.102(a), citing Abiomed's exclusive authorization to service proprietary Impella diagnostic software and calibration tools unavailable to competitors.

Customer concentration sits heavily with the Department of Veterans Affairs across multiple Veterans Integrated Service Networks. The top three customers by potential value account for 65% of combined potential value: VISN 12 (72 awards, $70.4 million), VISN 22 (107 awards, $46.6 million), and VISN 17 (116 awards, $18.3 million). By award count, VISN 17 leads with 116 awards followed by VISN 22 with 107 awards, together accounting for roughly 30% of total awards. The Department of the Army Medical Command places 82 awards valued at $7 million. Secondary exposure includes the Defense Health Agency, Defense Logistics Agency Troop Support Medical, and scattered orders from the Air Force and Navy medical commands. Combined obligated dollars across all awards stand at $112.9 million against a $241 million combined potential value, yielding a 47% obligation rate consistent with indefinite delivery vehicles and purchase orders with option years.

Abiomed holds three named single-award indefinite delivery contracts as its primary vehicles: a $238,591 IDIQ with VISN 17 (awarded August 31, 2024, expiring July 31, 2029) for service agreement and Impella coverage at Houston, Texas; a $242,500 IDIQ with VISN 4 (awarded June 14, 2024, expiring June 13, 2029) for preventative maintenance and repair of Impella balloon pumps at VA Medical Centers in Philadelphia and Wilkes-Barre, Pennsylvania; and a $221,237 IDIQ with VISN 4 (awarded March 31, 2023, expiring March 30, 2024) for maintenance and repair of ventricular assist devices at Wilkes-Barre and Pittsburgh, Pennsylvania. The overwhelming majority of awards—846 task orders valued at $159.2 million—flow through the Medical Equipment and Supplies GSA Schedule (FSS-65-II-A), which serves as Abiomed's primary contracting vehicle for delivery orders across the VA system. A single blanket purchase agreement with VISN 23 (awarded February 22, 2022, expiring February 21, 2024) for Impella Catheter devices carried a $703,517 ceiling and three firm fixed-price call orders totaling approximately that amount.

Award activity has remained steady at 77–83 awards annually from 2022 through 2024, declining sharply to 18 awards in 2025 and 9 awards in 2026; the 2025–2026 decline reflects the source data capture window ending mid-year 2026 and does not indicate market loss. Abiomed operates across 36 distinct federal customer agencies, with the VA system accounting for the vast majority of business. Twenty-three awards carrying $2.8 million in combined potential value reach ultimate completion within the next twenty-four months, creating recompete exposure primarily in routine maintenance task orders against the GSA Schedule and IDIQ vehicles. The company's award footprint is concentrated in NAICS 339112 (Surgical and Medical Instrument Manufacturing) and 334517 (Electromedical and Electrotherapeutic Apparatus Manufacturing), with PSC coding dominated by Medical and Surgical Instruments, Equipment, and Supplies (1,255 awards) and maintenance/repair services (211 awards). Abiomed received a single federal grant sub-award as a subawardee under Johns Hopkins University on a March 7, 2025 award for the IRONMAN (Innovative Resuscitation and Optimized Novel Multi-organ support with Autonomous ECMO for Non-medical personnel and medics) program, representing minimal grant exposure relative to its contract-dominant posture.